RxDoctor Payments DataLook up a doctor →

Robert Brennan, MD

Infectious Disease · Lynchburg, VANPI 1659355170

Payments from drug & device makers

$737,687in general payments, 2019–2025

Across 185 payments — averaging $3987.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$509K
  • Janssen Research & Development, LLC$147K
  • Sanofi Pasteur Inc.$39K
  • Chiesi USA, Inc.$26K
  • GSK$17K
  • Amgen$30
  • plus $130 from 6 others

What the payments were for

  • Food & beverage$13584%
  • Education$2516%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$737,687 in reported general payments places this provider in the 95th percentile of 194 infectious disease providers in Virginia.

See all infectious disease providers in Virginia

Medicare billing

Part B allowed, 2024
$27,037,544
Medicare patients
2,437
Services billed
1,273,395

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala49$198,943
DescovyEmtricitabine/Tenofov Alafenam28$65,490
TriumeqAbacavir/Dolutegravir/Lamivudi14$59,808
JulucaDolutegravir/Rilpivirine15$58,753
GenvoyaElviteg/Cob/Emtri/Tenof Alafen14$53,648
TivicayDolutegravir Sodium21$47,471
Daptomycin21$23,487
ErtapenemErtapenem Sodium14$4,855
CeftriaxoneCeftriaxone Sodium32$2,949
Ampicillin Sodium11$1,791
Efavirenz11$749
Sodium Chloride0.9 % Sodium Chloride51$301
Ciprofloxacin Hcl15$234
Amoxicillin14$189

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyTriumeq, Juluca, Tivicay$509,248$166,03250 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 194 infectious disease providers in Virginia.

Other infectious disease in Lynchburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →